TEVA Q2 2022 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.8B-3.2% YoY

Gross Profit

$1.8B47.4% margin

Operating Income

-$949M-25.1% margin

Net Income

-$232M-6.1% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+3.4%

Cash Flow

Operating Cash Flow

$123M

Free Cash Flow

-$4M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$45.9B

Total Liabilities

$36.1B

Stockholders' Equity

$9.0B

Cash & Equivalents

$2.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.9B	-3.2%
Gross Profit	$1.8B	$1.9B	-4.2%
Operating Income	-$949M	$582M	-263.1%
Net Income	-$232M	$207M	-212.1%

Revenue Segments

Product

$3.3B87%

Distribution Service

$318M8%

Product and Service, Other

$106M3%

License

$72M2%

Geographic Segments

North America Segment

$1.9B54%

Europe Segment

$1.2B33%

International Markets

$454M13%